Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
July 16, 2018 06:59 ET
|
Spero Therapeutics, Inc.
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...
Spero Therapeutics Announces Pricing of Securities Offering
July 12, 2018 20:10 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Proposed Offering of Common Stock
July 09, 2018 16:10 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
July 09, 2018 07:30 ET
|
Spero Therapeutics, Inc.
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending dosesData support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to...
Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
June 05, 2018 08:00 ET
|
Spero Therapeutics, Inc.
Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass., June 05, 2018 ...
Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
June 01, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
May 23, 2018 08:00 ET
|
Spero Therapeutics, Inc.
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and...
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
May 10, 2018 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
May 01, 2018 09:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
April 16, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...